View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Takeda’s blood-based alternative to a Covid-19 vaccine

By Jamie Bell

Whether it’s starting from scratch to develop an entirely novel vaccine, or testing the effectiveness of an existing vaccination on Covid-19, healthcare companies across the globe have been working day and night to find an effective treatment to immunise patients against the virus.

While the vast majority of these efforts involve small-molecule drugs, Japanese pharma firm Takeda has opted to tackle the infection more directly using blood plasma.

The Osaka-headquartered company has worked on plasma-derived therapies for more than 75 years, and for the past two months has been attempting to develop one such treatment for high-risk patients already infected with SARS-CoV-2, the virus that causes Covid-19.

Read the full article here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena